Two-Stage Classification of Breast Tumor Biomarkers for Iraqi Women
Objective: Breast cancer is regarded as a deadly disease in women causing lots of mortalities. Early diagnosis of breast cancer with appropriate tumor biomarkers may facilitate early treatment of the disease, thus reducing the mortality rate. The purpose of the current study is to improve early diagnosis of breast by proposing a two-stage classification of breast tumor biomarkers fora sample of Iraqi women.
Methods: In this study, a two-stage classification system is proposed and tested with four machine learning classifiers. In the first stage, breast features (demographic, blood and salivary-based attributes) are classified into normal or abnormal cases, while in the second stage the abnormal breast cases are further classified into either malignant or benign. The collected 20 breast cancer features are utilized to test the performance of the proposed classification system with Leave-One-Out (LOO) cross validation and Synthetic Minority Over-Sampling Technique (SMOTE) to balance the classes. Furthermore, correlation-based feature selection (CFS) was employed in an exploratory analysis to find the best features for the 2-stage classification system.
Results: Classification accuracy of 94% for stage-1 and 100% for stage-2was achieved with a Naïve Bayesclassifier which outperformed other three methods. In addition, CFS selected small subset of features as being the best five features out of the all 20 features for both stage-1 and stage-2.
Conclusion: We achieved a high classification accuracy which is promising to help improve the early diagnosis of breast tumor. The outcome of this study also shows the importance of CA15-3protein in saliva and blood as well as carcinoembryonic antigen level and total protein in blood, and Estrogen hormone level in saliva, for predicting breast tumors.
(Received 18 November 2019; accepted 26 April 2020)
Copyright: Open Access authors retain the copyrights of their papers, and all open access articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.